ClinicalTrials.gg
CompletedNCT00777023Updated Feb 22, 2012Results posted

Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

A Phase 3 interventional study of Gabapentin Extended-Release (G-ER) 1200 mg and Gabapentin Extended-Release (G-ER) 1800 mg in Hot Flashes, sponsored by Depomed. Completed at 45 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-22.

Sponsored by Depomed · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
565
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing gabapentin in Hot Flashes — none open to participants now, none under way, none of them phase 3. Gabapentin · Hot Flashes.

Enrollment
2nd of 10
565 · median 160
Started
2008
with 1 other
Phase 3
6 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
4 of 11
Depomed

Among the 11 studies testing gabapentin in Hot Flashes, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 7th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 11 studies testing gabapentin in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing gabapentin in Hot Flashes as a file.
02

Study summary

Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women

Read the detailed description

The primary study objective is to assess the efficacy of G-ER dosed in either of the following regimens:

G-ER 1200mg daily (single evening dose)

G-ER 1800mg daily (dosed asymmetrically; 600mg AM/1200mg PM)

compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women after 4 weeks and 12 weeks of treatment with a stable dose, compared with the baseline week.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Hot Flashes
  • Hot Flushes
  • Postmenopausal symptoms
  • Vasomotor symptoms
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women aged 18 to 70 years experiencing ≥7 moderate to severe hot flashes per day (or ≥50 per week) accompanied by sweating during previous 30 days or longer.
  2. Had amenorrhea for ≥12 months, amenorrhea for 6 to 12 months with serum follicle-stimulating hormone (FSH) levels >40 mIU/mL, or was ≥6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  3. Willing to discontinue the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; intrauterine progestin; progestin implants; injectable estrogen; topical progesterone cream.
  4. Had to have daily average of ≥7 moderate to severe hot flashes and had to complete ≥4 days of diary entries during baseline week to be randomized.
  5. If treated with antidepressants, could not have had any changes in drug doses during past month.

Other Inclusions apply.

Exclusion criteria

Exclusion Criteria:

  1. Patient treated with a gonadotrophin releasing hormone agonist, anti-estrogens, or aromatase inhibitors within 2 months prior to study entry.
  2. Patient treated with estrogen pellets or progestin injectable drugs within 6 months prior to study entry.
  3. Patient experience only nighttime hot flashes or worked night shifts on a regular basis.
  4. Patient was concurrently treated with gabapentin for other indications. If patient was using gabapentin for treatment of hot flashes, she could be screened after a 7-day provided hot flashes returned.
  5. Patient had previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.
  6. Patient had a to gabapentin.
  7. Patient was in an state.
  8. Patient had a other than basal cell carcinoma within 2 years prior to study entry.
  9. Patient had gastric reduction surgery, severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome, uncontrolled inflammatory bowel disease, or unexplained weight loss.
  10. Patient had abnormal chemistry or hematology results, or calculated \<60 mL/min.
  11. Patient had history of substance abuse within year prior to study entry.
  12. Patient was concurrently taking morphine.
  13. Patient had history of chronic or C, hepatitis within 3 months prior to study entry, or history of .

Other Exclusions apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
565 participants (actual)

Study arms

  • Experimental
    G-ER 1200 mg

    Gabapentin extended-release (G-ER) 1200 mg

    Drug: Gabapentin Extended-Release (G-ER) 1200 mg

  • Experimental
    G-ER 1800 mg

    Gabapentin extended-release (G-ER) 1800 mg

    Drug: Gabapentin Extended-Release (G-ER) 1800 mg

  • Placebo comparator
    Sugar Pill

    Placebo 1200 mg or 1800 mg

    Drug: Placebo

Interventions

  • G-ER 1200 mg daily dosage given as two 600-mg tablets.

    Also known as: Gabapentin

  • G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.

    Also known as: Gabapentin

  • DrugPlacebo

    Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).

    Also known as: Placebo; sugar pill

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment

    Mean change from baseline in average daily number of moderate or severe hot flashes at stable dose week (SDW) 4 of treatment relative to placebo; last observation carried forward (LOCF) analysis

    Time frame: At baseline and 4 weeks of treatment

  2. Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 12 Weeks of Treatment

    Mean change from baseline in average daily number of moderate or severe hot flashes at stable dose week (SDW) 12 of treatment relative to placebo; last observation carried forward (LOCF) analysis

    Time frame: At baseline and 12 weeks of treatment

  3. Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 4 Weeks of Treatment

    Mean change from baseline in average daily severity score of moderate or severe hot flashes at stable dose week (SDW) 4 of treatment relative to placebo; last observation carried forward (LOCF) analysis. Severity of hot flashes is scored on a scale of 1 to 3 where 1=mild, 2=moderate, 3=severe.

    Time frame: At baseline and 4 weeks of treatment

  4. Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 12 Weeks of Treatment

    Mean change from baseline in average daily severity score of moderate or severe hot flashes at stable dose week (SDW) 12 of treatment relative to placebo; last observation carried forward (LOCF) analysis. Severity of hot flashes is scored on a scale of 1 to 3 where 1=mild, 2=moderate, 3=severe.

    Time frame: At baseline and 12 weeks of treatment

07

Results

Posted Feb 17, 2012

Participant flow

Participant flow — Overall Study
MilestoneG-ER 1200 mgG-ER 1800 mgSugar Pill
Started186190183
Completed151149146
Not completed354137
Withdrew: Adverse event15218
Withdrew: Lack of efficacy1014
Withdrew: Protocol violation211
Withdrew: Lost to follow-up233
Withdrew: Death010
Withdrew: Withdrawal by subject778
Withdrew: Missing data110
Withdrew: Reasons not specified442
Withdrew: Last dose date unknown331

Outcome measures

PrimaryChange From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment

Mean change from baseline in average daily number of moderate or severe hot flashes at stable dose week (SDW) 4 of treatment relative to placebo; last observation carried forward (LOCF) analysis

Time frame:
At baseline and 4 weeks of treatment
Reported as:
Least squares mean · Hot flashes
Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment
Hot flashesG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment-7.0 (-7.77 to -6.19)-6.9 (-7.68 to -6.08)-5.4 (-6.18 to -4.46)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.0024 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1200 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -1.61 · 97.5% CI -2.80 to -0.42
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0040 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1800 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -1.51 · 97.5% CI -2.69 to -0.33
PrimaryChange From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 12 Weeks of Treatment

Mean change from baseline in average daily number of moderate or severe hot flashes at stable dose week (SDW) 12 of treatment relative to placebo; last observation carried forward (LOCF) analysis

Time frame:
At baseline and 12 weeks of treatment
Reported as:
Least squares mean · Hot flashes
Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 12 Weeks of Treatment
Hot flashesG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 12 Weeks of Treatment-7.7 (-8.50 to -6.97)-7.3 (-8.06 to -6.52)-6.2 (-6.96 to -5.38)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.0024 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1200 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -1.56 · 97.5% CI -2.72 to -0.41
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0281 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1800 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -1.12 · 97.5% CI -2.26 to 0.02
PrimaryChange From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 4 Weeks of Treatment

Mean change from baseline in average daily severity score of moderate or severe hot flashes at stable dose week (SDW) 4 of treatment relative to placebo; last observation carried forward (LOCF) analysis. Severity of hot flashes is scored on a scale of 1 to 3 where 1=mild, 2=moderate, 3=severe.

Time frame:
At baseline and 4 weeks of treatment
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 4 Weeks of Treatment
Units on a scaleG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 4 Weeks of Treatment-0.5 (-0.63 to -0.40)-0.6 (-0.76 to -0.53)-0.4 (-0.49 to -0.25)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.0608 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1200 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -0.15 · 97.5% CI -0.32 to -0.03
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0003 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1800 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -0.28 · 97.5% CI -0.45 to -0.11
PrimaryChange From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 12 Weeks of Treatment

Mean change from baseline in average daily severity score of moderate or severe hot flashes at stable dose week (SDW) 12 of treatment relative to placebo; last observation carried forward (LOCF) analysis. Severity of hot flashes is scored on a scale of 1 to 3 where 1=mild, 2=moderate, 3=severe.

Time frame:
At baseline and 12 weeks of treatment
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 12 Weeks of Treatment
Units on a scaleG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 12 Weeks of Treatment-0.8 (-0.90 to -0.61)-0.8 (-0.97 to -0.68)-0.5 (-0.69 to -0.39)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.0280 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1200 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -0.21 · 97.5% CI -0.43 to 0.00
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0026 (P value for pairwise test of difference of least square mean change from baseline between G-ER 1800 mg and placebo groups based on F test of type III analysis.) · Mean difference (net): -0.29 · 97.5% CI -0.51 to -0.07

Adverse events

Collected over Adverse events collected for total of 13 weeks: from baseline to end of stable dosing week (SDW) 12 (treatment Week 13; end-of-treatment period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-ER 1200 mg—2/186 (1.1%)70/186 (37.6%)
G-ER 1800 mg—2/190 (1.1%)83/190 (43.7%)
Sugar Pill—2/183 (1.1%)29/183 (15.8%)
Most frequent serious events
Most frequent serious events
EventG-ER 1200 mgG-ER 1800 mgSugar Pill
Road traffic accidentInjury, poisoning and procedural complications0/1860/1901/183
Meniscus lesionInjury, poisoning and procedural complications0/1860/1901/183
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1860/1900/183
Overdose; attempted suicideInjury, poisoning and procedural complications1/1860/1900/183
Chest painGeneral disorders0/1861/1900/183
Accidental overdoseInjury, poisoning and procedural complications0/1861/1900/183
Most frequent other events
Most frequent other events
EventG-ER 1200 mgG-ER 1800 mgSugar Pill
DizzinessNervous system disorders32/18636/1905/183
SomnolenceNervous system disorders13/18616/1906/183
HeadacheNervous system disorders9/18614/19014/183
NauseaGastrointestinal disorders6/18614/1903/183
SedationNervous system disorders10/1863/1901/183

Baseline characteristics

Age Continuous
Age Continuous(years)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
Mean53.1 ± 7.053.6 ± 6.152.9 ± 6.053.2 ± 6.4
Age, Customized
Age, Customized(participants)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
<65 years175181177533
>=65 years119626
Sex: Female, Male
Sex: Female, Male(Participants)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
Female186190183559
Male0000
Frequency of hot flashes
Frequency of hot flashes(Hot flashes)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
Mild1.1 ± 2.01.0 ± 2.01.7 ± 2.91.2 ± 2.3
Moderate6.1 ± 5.85.4 ± 4.06.2 ± 5.15.9 ± 5.0
Severe6.7 ± 5.16.9 ± 5.56.6 ± 4.96.8 ± 5.2
08

Study locations

45 sites
  • Radiant Research
    Birmingham, Alabama 35209, United States
  • Star W Research
    Chandler, Arizona 85225, United States
  • Radiant Research
    Scottsdale, Arizona 85251, United States
  • May Women's Health Clinic
    Little Rock, Arkansas 72205, United States
  • Family Medical Center
    Foothill Ranch, California 92610, United States
  • Genesis Center for Clinical Research
    San Diego, California 92103, United States
  • San Diego, California 92103, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Milestone Medical Research, Inc.
    Englewood, Colorado 80112, United States
  • Danbury Clinical Research, LLC
    Danbury, Connecticut 06810, United States
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
  • Meridien Research
    Bradenton, Florida 34203, United States
  • Meridien Research
    Brooksville, Florida 34601, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Southeastern Integrated Medical, PL
    Gainsville, Florida 32607, United States
  • Sunrise Medical Research
    Lauderdale Lakes, Florida 33319, United States
  • University Clinical Research, Inc.
    Pembroke Pines, Florida 33024, United States
  • Radiant Research - St. Petersburg
    Pinellas Park, Florida 33781, United States
  • Atlanta Women's Research Institute, Inc.
    Atlanta, Georgia 30342, United States
  • Atlanta West Women's Center
    Douglasville, Georgia 30134, United States
  • Physician's Research Group
    Indianapolis, Indiana 46250, United States
  • West Bank Women's Health
    Marrero, Louisiana 70072, United States
  • ActivMed Practices and Research
    Haverhill, Massachusetts 01830, United States
  • Women's Health Care Specialists, PC
    Paw Paw, Michigan 49079, United States
  • Saginaw Valley Medical Research Group, LLC
    Saginaw, Michigan 48604, United States
  • Aspen Medical Group
    St. Paul, Minnesota 55108, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • Williamsburg Boro Park ObGyn, PC
    New York, New York 11211, United States
  • Pinewest Ob-Gyn, Inc.
    High Point, North Carolina 27262, United States
  • Mid Dakota Clinic, PC
    Bismarck, North Dakota 58501, United States
  • Radiant Research, Inc.
    Cincinnati, Ohio 45249, United States
  • Rapid Medical Research, Inc.
    Cleaveland, Ohio 44122, United States
  • Columbus Center for Women's Health Research
    Columbus, Ohio 43213, United States
  • Clinical Trials of America, Inc.
    Eugene, Oregon 97401, United States
  • PMG/OB Gyn Health Center
    Medford, Oregon 97504, United States
  • The Clinical Trial Center, LLC
    Jenkintown, Pennsylvania 19046, United States
  • Upstate Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Coastal Carolina Research Center, Inc.
    Mt. Pleasant, South Carolina 29464, United States
  • Alpha Clinical Research, LLC
    Clarksville, Tennessee 37043, United States
  • Clinical Research Investigative Services, LLC
    Knoxville, Tennessee 37923, United States
  • Mid-South OB-GYN, PLLC
    Memphis, Tennessee 38120, United States
  • Renaissance Clinical Research and Hypertension Clinic
    Dallas, Texas 75235, United States
  • InVisions Consultants, LLC
    San Antonio, Texas 78217, United States
  • Radiant Research, Inc.
    Salt Lake City, Utah 84107, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jul 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2008
First posted
Oct 22, 2008
Start
Oct 2008
Primary completionActual
Jul 2009
CompletionActual
Oct 2009
Results first posted
Feb 17, 2012
Last update
Feb 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00777023
Lead sponsor
Depomed
Responsible party
Sponsor
First posted
Oct 22, 2008
Start date
Oct 2008
Primary completion
Jul 2009
Completion
Oct 2009
Results posted
Feb 17, 2012
Last update
Feb 22, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion